Companies Dominating the Antibody Validation Landscape
- General Electric
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck KGaA
- Thermo Fisher Scientific Inc.
- F. Hoffmann La-Roche Ltd
- Rockland Immunochemicals Inc.
- Johnson & Johnson private Limited
- Agilent Technologies Inc.
- Eli Lily and Company
- Becton, Dickinson and Company
- Danaher
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of antibody validation is evaluated at USD 476.39 billion.
The antibody validation market size was over USD 387.49 billion in 2024 and is poised to exceed USD 2.03 trillion by 2037, growing at over 13.6% CAGR during the forecast period i.e., between 2025-2037. The market growth is driven by growing prevalence of autoimmune disease, the rise in the need for early detection of cancer, and the advancement of strategies.
North America industry is predicted to dominate majority revenue share of 30% by 2037, backed by growing prevalence of HIV, along with rising investment in research and development.
The major players in the market are General Electric, Merck KGaA, Thermo Fisher Scientific Inc., F. Hoffmann La-Roche Ltd, Rockland Immunochemicals Inc., Johnson & Johnson private Limited, Agilent Technologies Inc., Eli Lily and Company, Becton, Dickinson and Company, Danaher
